Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 06.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
| 06.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 24.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | . ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certa |
| 23.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ge Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 10.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Cer |
| 10.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 8-K”) solely to provide information required by Item 5.02(d)(3) that was undetermined at the time of filing of the Initi |
| 06.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
Stammdaten
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Unternehmen & Branche
| Name | DiaMedica Therapeutics Inc. |
|---|---|
| Ticker | DMAC |
| CIK | 0001401040 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 336,3 Mio. USD |
| Beta | 1,15 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -32,766,000 | 61,371,000 | 56,111,000 | ||
| 2025-09-30 | 10-Q | -8,620,000 | 57,047,000 | 51,622,000 | ||
| 2025-06-30 | 10-Q | -7,699,000 | 31,470,000 | 27,170,000 | ||
| 2025-03-31 | 10-Q | -7,707,000 | 38,830,000 | 33,954,000 | ||
| 2024-12-31 | 10-K | -24,444,000 | 46,345,000 | 40,718,000 | ||
| 2024-09-30 | 10-Q | -6,274,000 | 52,524,000 | 47,964,000 | ||
| 2024-06-30 | 10-Q | -5,119,000 | 56,791,000 | 53,415,000 | ||
| 2024-03-31 | 10-Q | -5,151,000 | 49,260,000 | 46,349,000 | ||
| 2023-12-31 | 10-K | -19,381,000 | 54,160,000 | 51,057,000 | ||
| 2023-09-30 | 10-Q | -4,471,000 | 58,139,000 | 55,629,000 | ||
| 2023-06-30 | 10-Q | -4,477,000 | 62,050,000 | 59,743,000 | ||
| 2023-03-31 | 10-Q | -5,272,000 | 30,217,000 | 27,022,000 | ||
| 2022-12-31 | 10-K | -13,676,000 | 34,395,000 | 31,827,000 | ||
| 2022-09-30 | 10-Q | -3,059,000 | 37,041,000 | 35,079,000 | ||
| 2022-06-30 | 10-Q | -3,358,000 | 39,258,000 | 37,715,000 | ||
| 2022-03-31 | 10-Q | -3,508,000 | 42,211,000 | 40,768,000 | ||
| 2021-12-31 | 10-K | -13,592,000 | 45,551,000 | 44,024,000 | ||
| 2021-09-30 | 10-Q | -3,450,000 | 48,664,000 | 47,036,000 | ||
| 2021-06-30 | 10-Q | -3,274,000 | 21,774,000 | 20,318,000 | ||
| 2021-03-31 | 10-Q | -3,622,000 | 24,356,000 | 23,145,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.